您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > (R)-Crizotinib
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
(R)-Crizotinib
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
(R)-Crizotinib图片
CAS NO:877399-52-5
规格:98%
分子量:450.34
包装与价格:
包装价格(元)
10mg电议
50mg电议
100mg电议

产品介绍
C-MET/ALK inhibitor,potent and ATP-competitve
CAS:877399-52-5
分子式:C21H22Cl2FN5O
分子量:450.34
纯度:98%
存储:Store at -20°C

Background:

Crizotinib is a potent, ATP-competitive, small-molecule and orally available inhibitor of c-Met kinase with a Ki value?of 4 nmol/L[1].


Crizotinib has shown to inhibit?wild-type c-Met phosphorylation with a mean IC50 value of 11 nmol/L in multiple human endothelial and carcinoma cell lines. Crizotinib has been demonstrated to inhibit cell growth and induce apoptosis in?human GTL-16 gastric carcinoma cells. Additionally, crizotinib could inhibit cell migration and invasion induced by HGF in human NCI-H441 lung cancer cells. Moreover, crizotinib has revealed to block cell scattering of MDCK [1].


Crizotinib has been indicated to suppress tumor growth in GTL-16, NCI-H441 NSCLC, Caki-1 RCC, U87MG glioblastoma or PC-3 prostate tumor xenograft mice [1].


参考文献:
[1] Zou HY1,?Li Q,?Lee JH,?Arango ME,?McDonnell SR,?Yamazaki S,?Koudriakova TB,?Alton G,?Cui JJ,?Kung PP,?Nambu MD,?Los G,?Bender SL,Mroczkowski B,?Christensen JG. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res.?2007 May 1;67(9):4408-17.